Central role of β-catenin in anticancer effects of cardiac hormones

• Published in: Anticancer research 2013-06, Vol.33 (6), p.2409-2414
• Main Authors: Skelton, 4th, William P, Skelton, Michelle, Vesely, David L
• Format: Article
• Language: English
• Subjects: Adenocarcinoma - drug therapy; Animals; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Atrial Natriuretic Factor - pharmacology; Atrial Natriuretic Factor - therapeutic use; beta Catenin - antagonists & inhibitors; beta Catenin - metabolism; Cell Line, Tumor; Colonic Neoplasms - drug therapy; Colorectal Neoplasms - drug therapy; Humans; Kidney Neoplasms - drug therapy; Mice; Pancreatic Neoplasms - drug therapy; Peptide Fragments - pharmacology; Peptide Fragments - therapeutic use; Protein Precursors - pharmacology; Protein Precursors - therapeutic use
• ISSN: 0250-7005; 1791-7530

β-Catenin causes malignant growth of colonic, pancreatic and renal cancer. Four cardiac hormones, namely atrial natriuretic peptide (ANP), vessel dilator, long-acting natriuretic peptide (LANP) and kaliuretic peptide eliminate up to 80% of human pancreatic carcinomas growing in mice. Four cardiac hormones were evaluated for their ability to reduce the expression of human β-catenin, measured by enzyme-linked immunosorbent assay (ELISA) in human colorectal, pancreatic and renal cancer cells. Vessel dilator, LANP, kaliuretic peptide, and ANP, over a concentration range of 100 pM to 10 μM, maximally reduced expression of β-catenin in human colorectal cancer cells by 78%, 71%, 69%, and 83%, respectively. Vessel dilator, LANP, kaliuretic peptide, and ANP reduced β-catenin expression in human pancreatic cancer cells by 76%, 66%, 72%, and 88%, and by 64%, 54%, 58% and 73%, in human renal cancer cells, respectively. Part of the anticancer action of these four cardiac hormones is a potent inhibition of β-catenin.